ARTICLE | Emerging Company Profile
ONK’s CAR NK cells hit the TRAIL
Emerging Company Profile: Ireland’s ONK Therapeutics soups up CAR NK cells with TRAIL variants
January 23, 2021 12:02 AM UTC
ONK thinks its engineered TRAIL variants will make CAR NK cells more potent and resistance-proof against both hematological and solid cancers.
The company, which spun out of National University of Ireland Galway in 2015, has applied its dual targeting allogeneic NK cell platform to four preclinical programs...